PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

BACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disease with a poor survival, characterized by the accumulation of myeloma cells (MMCs) within the bone marrow. Epigenetic modifications in MM are associated not only with cancer development and progression, but also with drug resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Herviou, Laurie, Kassambara, Alboukadel, Boireau, Stéphanie, Robert, Nicolas, Requirand, Guilhem, Müller-Tidow, Carsten, Vincent, Laure, Seckinger, Anja, Goldschmidt, Hartmut, Cartron, Guillaume, Hose, Dirk, Cavalli, Giacomo, Moreaux, Jerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171329/
https://www.ncbi.nlm.nih.gov/pubmed/30285865
http://dx.doi.org/10.1186/s13148-018-0554-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171329/
https://www.ncbi.nlm.nih.gov/pubmed/30285865
http://dx.doi.org/10.1186/s13148-018-0554-4

Ejemplares similares